VX-445

March 8, 2019March 26, 2019

Positive Data from VX-445 Triple Combo Regimen Prompt Vertex to Seek Regulatory Approval

News

Vertex Pharmaceuticals is planning to request regulatory approval from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) during the third and fourth quarters of 2019, ... Read more

November 29, 2018November 29, 2018

Triple Combo with VX-659 Improves Lung Function in CF Patients with F508del Mutation, Phase 3 Trials Show

cystic fibrosis, News

Treatment with a triple combination — the new CFTR corrector VX-659, together with tezacaftor and Kalydeco (ivacaftor) — significantly improved lung function and was well-tolerated by cystic fibrosis (CF) patients, ages 12 ... Read more

October 30, 2018October 30, 2018

VX-445 Triple Combo Improves Lung Function in CF Patients with F508del Mutations, Phase 2 Trial Shows

cystic fibrosis, News

Adding the investigational therapy VX-445 to tezacaftor (VX-661) and Kalydeco (ivacaftor) led to a roughly 10 percent improvement in the lung function of cystic fibrosis (CF) patients with F508del mutations in the CFTR gene ... Read more

October 25, 2018October 25, 2018

#NACFC2018 — Vertex Presents Latest Clinical Data on CFTR Modulators

cystic fibrosis, News

Vertex Pharmaceuticals’ VX-659 or VX-445 in combination with Kalydeco (ivacaftor) and tezacaftor (VX-661) can improve the lung function of patients with cystic fibrosis (CF) with one or two copies ... Read more

September 17, 2018September 17, 2018

Vertex and Treating CF: High Hopes for Triple Combinations and Gene Therapy Possibilities

cystic fibrosis

Editor’s note: This is third in a four-part series looking at Vertex Pharmaceuticals and its “all in for CF” approach. Here, we look at potential “next-generation” treatments that range from ... Read more

September 11, 2018September 12, 2018

Two Phase 3 Trials of Vertex’s Triple Combination Therapy with VX-659 Are Fully Enrolled

cystic fibrosis, News

Vertex Pharmaceuticals has completed enrollment for two Phase 3 studies testing the triple combination therapy of its new CFTR corrector VX-659 together with tezacaftor (VX-661) and Kalydeco (ivacaftor) in patients with cystic ... Read more

July 27, 2018July 27, 2018

Vertex Anticipates Completing Enrollment of Phase 3 Trials Testing Triple Combo Therapies

cystic fibrosis, News

Vertex Pharmaceuticals plans to conclude the enrollment of patients in its Phase 3 programs involving its triple combo therapies to treat cystic fibrosis (CF) in the second half of 2018, the ... Read more

June 18, 2018June 18, 2018

Vertex Employees Donate $1M to CF and Other Communities via Matching Gift Program

cystic fibrosis, News

Vertex Pharmaceuticals employees have raised more million $1 million using the Vertex Foundation‘s matching gift program in a show of commitment to causes that include the cystic fibrosis (CF) community, a company press ... Read more

May 4, 2018May 4, 2018

Vertex Awards $400K in Scholarships to CF Patients, Family Members

cystic fibrosis, News

Vertex Pharmaceuticals recently awarded $400,000 in scholarships for people living with cystic fibrosis (CF) and their family members, as part of its second “All in for CF” scholarship program. ... Read more

May 2, 2018May 2, 2018

Vertex Announces VX-445 Phase 3 Trial Program, Positive Data on VX-561 Combo Regimen

cystic fibrosis, News

Vertex Pharmaceuticals is launching Phase 3 clinical trials to evaluate the safety and effectiveness of its investigational therapy, VX-445, in combination with VX-661 (tezacaftor) and Kalydeco (ivacaftor) for cystic fibrosis ... Read more

Pin It on Pinterest